SCHEMBL14096284

SCHEMBL14096284

CCCCCOc1ccc(NC(=S)NC(=O)c2ccc(N3CCOCC3)nc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.54
ALDH1A1 P00352 10/20 0.54
MAPK1 P28482 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
NPC1 O15118 2/20 0.52
SMN1; SMN2 Q16637 4/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.49
GAA P10253 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2C19 P33261 1/20 0.49
EPHX1 P07099 1/20 0.48
RAB9A P51151 1/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3146323 0.90 MAPT (0.58) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3145971 0.90 MAPT (0.52) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3151131 0.87 KCNQ3 (0.49) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3146118 0.86 MAPT (0.58) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3150338 0.85 MAPT (0.57) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3150260 0.85 MAPT (0.57) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3155355 0.85 NPC1 (0.54) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3146277 0.85 NPC1 (0.54) MAPTALDH1A1MAPK1TDP1KMT2A
SCHEMBL3136511 0.84 THRB (0.52) MAPTALDH1A1MAPK1TDP1KMT2A
Morpholine SCHEMBL27782736 0.81 MAPT (0.48) MAPTALDH1A1MAPK1TDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv ACHILLION PHARMACEUTICALS, INC. (US) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207760-A1 Pharmaceutical Compositions For and Methods of Inhibiting Hcv RNASE1, SARS1, EIF2AK2 MAPT 4038/4885ALDH1A1 2930/4885MAPK1 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.